The mushroom shaped outer spike protein of influenza, neuraminidase, was first discovered nearly 60 years ago. Its importance in viral replication was soon recognised both at the point of viral release from the cell and also enabling passage of virus through nasal fluid to reach the cell. The enzyme active site was identified by x-ray crystallography, allowing an atomic study of interaction of enzyme with the sialic acid substrate. Analogues could then be identified and synthesized and became a focused target for antivirals. With the current threat of bioterrorism and the potential for the emergence of a new pandemic strain in the near future, efforts are underway to develop more potent second-generation anti-neuraminidase inhibitors with enhanced protective and therapeutic effects. Here we review older and newer neuraminidase inhibitors and the role that they will play in the fight against influenza in its epidemic and pandemic face.
For more than 60 years it had been appreciated that influenza virus possessed a rather unique enzyme that cleaved sialic acid from sialylated glycoproteins (Hoyle, 1950) . It was termed sialidase although neuraminidase is the noun used today. Sialic acid is the receptor for the influenza virus on mammalian cells and red blood cells. Only after painstaking work by biochemists and electron microscopists had defined two surface spikes on the influenza virus, was one of them, a strikingly long stalked mushroom, identified as the neuraminidase (NA). Laver (1964) was able to use cellulose acetate strips to separate and purify NA and Schild (Schild & Newman, 1969) refined the immuno-double diffusion test to further probe the characteristics of this protein. Palese & Schulman (1976) identified the gene coding for NA. However, it must be admitted that NA always had a secondary position in the structural virology of influenza. The protein of dominant interest was the other spike, the haemagglutinin (HA), not so prepossessing in morphology but with some very important properties, particularly the ability to induce powerful neutralising antibodies. Furthermore, it has to be admitted the HA was easier to study. There were five (HA) spikes to every one NA and they were easier to purify. By chance the protease (bromelain) enzyme most used by biochemists to release the HA from the virus (by cleaving off a small portion of its hydrophobic tail end whereby it was attached to the virus membrane) at the same time completely cleaved the NA into small pieces. Thus, the HA could be neatly separated, purified and studied. Haemagglutinin was the first human virus protein to be crystallised (Wiley & Skehel, 1987) and its amino acid sequence could be correlated with structure. In comparison, the NA languished somewhat on the virological sidelines. Nevertheless, virologists studied the biology of the NA and came to appreciate some important properties of this protein. It became clear that antibody to NA could inhibit influenza viral replication but not by any conventional manner. Antibody appeared to reduce viral plaque size but not number (Kilbourne et al., 1968) . The implication was that anti-NA antibody inhibited release of virus from an infected cell. Experiments with influenza viruses with a ca or ts mutation in the NA gene identified viruses accumulating at the cell surface. Two chemists in Vienna (Meindl & Tuppy, 1969) had synthesised Neu5Ac2en, which also caused the virus to aggregate at the cell surfaces. The era of antiviral chemotherapy using the NA as target had begun, but there were to be long delays until, at the very turn of this millennium it became clear that a group of powerful Review New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors Introduction drugs had been discovered (reviewed by Gubareva et al., 2000) .
Do we need antiviral drugs against influenza?
The main clinical management of influenza as a disease is centred upon the use of prophylactic vaccine, mainly a subunit preparation of HA and NA spikes. Most European countries and the USA try to target at least 70% of their 'at risk' population for vaccination. This 'at risk' group is key to understanding the current approach to the management of influenza. No country has a wide immunisation strategy for two reasons. Firstly, the world production capacity for influenza vaccine is not large enough at present to cope with the changes to the vaccine required to keep up to date with the yearly antigenic changes of the virus itself and to produce virus for a mass vaccination campaign each year. Secondly, a large-scale vaccination would pressurise the virus to change faster antigenically by applying strong selective pressure on the HA and NA proteins of mixed quasi-species. Therefore, the 10% or so of persons over the age of 65 (in the EU, but over the age of 50 in the USA) are the targets of vaccinators, as well as persons of any age with asthma or chronic heart disease. It is quite clear that age is by itself a risk factor following an attack of influenza. This older community group finds itself more susceptible to virus-induced bronchitis and bronchopneumonia, and hence hospitalisation and death (reviewed in Stuart-Harris et al., 1983) . The vaccine has been shown very clearly in large clinical trials conducted over several seasons (Fedson et al., 1993) to reduce both hospitalisation and death by all causes. It should be appreciated that there are large numbers of influenza deaths in most countries of the world in most years. In the UK alone over the millennium period there were nearly 20000 deaths in a period of 4-5 week of pneumonia and bronchitis. These so-called excess deaths are attributed to influenza as an initial infection.
There is an alternative management strategy involving vaccine but to date it has been little explored and at first sight seems tenuous. There is clear evidence that influenza is predominantly a disease of childhood (reviewed by Betts & Treanor, 2000) . An innovative approach, therefore, is to immunise children and thereby break the chain of influenza transmission to parents and grandparents (Belshe et al., 1998) . A re-analysis of such vaccine data from Japan (Reichert et al., 2001) in the 1980s and to a lesser extent from towns in the USA (Monto et al., 1969) has shown some validity of this approach. However, in practical terms could parents be persuaded of this benefit and agree to have their child immunised with yet another vaccine? However, it is possible that an intranasally deliv-ered spray of live-attenuated vaccine could have a comparable effect and avert parental concerns.
Meanwhile, we are left with the clear observation that the 85% or so of the population, which is outside of the classical at risk group, remain vulnerable to influenza infection. Most of these persons will be ill for 5-7 days but there are still many deaths in persons outside the 'at risk' groups. It has been estimated that 40-50% of the 20000 deaths in the UK at the time of the Millennium were in the non-'at risk groups'. Therefore, there is a clear need for an intervention with antivirals in the wider community in persons outside the 'at risk' group.
There are two additional public health threats from influenza, the emergence of a new pandemic strain and the deliberate use of the virus as a threat in a terrorist scenario. The pandemic threat is taken very seriously and the WHO has published a pandemic template plan for all countries of the world (see below). The possible use of influenza in bioterrorism is, at present, much less likely than the actual emergence of a pandemic virus. Even the genetic determinants of the 1918 pandemic influenza, which caused the most serious global threat ever experienced by any microbe, are not yet known. However, the techniques of reverse genetics are now being used widely and it is conceivable in the medium term future that drug resistance mutations could be inserted into M1 and NA genes along with altered genes to enhance virulence. At present, no such attempts have been made to reconstruct the 1918 virus itself, although single genes and pairs of 1918 genes have been reassorted into another influenza A virus backbone.
X-ray crystallography of the influenza virus NA
X-ray crystallography revealed the positions of both enzyme active sites and antigenic epitopes of NA (Colman et al., 1983; Varghese et al., 1983) . The neuraminidase molecule is orientated rather unusually for a glycoprotein, its N-terminus being anchored in the viral membrane. After the 3-dimensional structure of influenza neuraminidase was established, the positions on the molecule of the catalytic site could be identified and the binding of inhibitory chemicals visualised. The molecule has a box-shaped head, with a unique folding pattern. Each monomer has six βsheets and contains four polypeptide strands. Viewed from above, each monomer has the appearance of a flower with the petals somewhat twisted to resemble a pinwheel ( Figure 1a ). The 'stem' is considered to span the bilayer of the virus with a hydrophobic stretch of amino acids. The catalytic site of the NA has been located by difference Fourier analysis of crystals soaked in sialic acid. The site is surrounded by 14 conserved charged residues and contains three hydrophobic residues -Tyr, Trp and Leu. The new anti-NA drugs bind to 11 of these critical amino acids ( Figure 1b ) and knowledge of the crystal structure allowed a design strategy of side groups to interact with crucial amino acids. Palese & Schulman (1977) were among the first virologists to exploit neuraminidase and its substrate sialic acid ( Figure 2a ) as a target for chemical inhibitors. The original neuraminic acid analogues (Meindl & Tuppy, 1969) were carefully investigated for anti-influenza effects on viral replication in cells. These drug transition state analogues were active at micromolar levels, reduced plaque size, caused virus to amass at the budding stage, but disappointingly after intraperitoneal administration had no effect in models of viral infection in the lung of a mouse. Essentially the key molecule, Neu5Ac2en (Figure 2b) , was a dehydrated neuraminidase acid derivative that mimicked the geometry of the transition state during the enzymatic reaction. In retrospect, intranasal or aerosol administration of drug could have given positive results in the animal models. However, to an extent NA was now identified as a target.
Scientific development of the anti-NA drugs
In the USA, Kilbourne was suggesting that a NA vaccine could have benefits compared with the conventional mixture of HA and NA. In Australia the Laver and Colman research teams (Colman et al., 1983; Varghese et al., 1983) were crystallising the NA protein for basic studies of structure and biology. Taking Neu5ac2en as the basic inhibitor a guanidinyl group was substituted for a hydroxyl carbon atom to make zanamivir (Relenza  ; Figure 2c ; Von Itzstein et al., 1993) . Another group of chemists designed a cyclohexene ring and replaced a polar glycerol with lipophilic side chains (Kim et al., 1998) : this is the drug oseltamivir (Tamiflu  ; Figure 2d ). The bioavailable drug is an ethyl ester that is converted into the active carboxylate ( Figure 2e ) by esterases in the liver. A third set of chemists designed a cyclopentane derivative with a guanidinyl group and lipophilic chains (Brouillette et al., 1999; Lou et al., 1997) . This drug is RWJ-270201 (also known as BCX-1812 or peramivir; Figure 2f ). All three drugs (zanamivir, oseltamivir and peramivir) were shown to be powerful inhibitors of influenza A and B virus NAs in enzyme tests (Table 1) , viral replication in culture (Table 2 ) and importantly in animal model infections using mice and ferrets. As expected in drug-treated cultures large viral aggregates can be detected at the cell surface by electron microscopy (Figure 3 ). All nine influenza A NA subtypes are inhibited at nmol levels. In contrast, a million times higher concentration of the drugs is needed to inhibit mammalian or bacterial neuraminidases. Early studies showed dose-dependent antiviral effects in mice and ferret models of influenza (reviewed by Gubareva et al., 2000; Laver et al., 1999; Oxford & Lambkin, 1998) . However, the polar zwitterionic properties of zanamivir gave low bioavailability and hence the drug was given by intranasal drops, whereas RWJ-270201 and oseltamivir could be given orally. All three drugs protected mice against lethal challenge with influenza A viruses including H5N1, which caused the outbreak in Hong Kong (Gubareva et al., 1998b) and was considered by some to be a candidate pandemic virus. The development of new anti-NA inhibitors does not come without its risks and hurdles but there are also great rewards to reap, both scientific and financial. An epidemic influenza year is very costly for the community in terms of hospitalisation. Elderly people with influenza may be treated easily for 7-10 days in the Royal London Hospital, for example, and this could cost £3000 in total. Therefore targeted prevention by neuraminidase inhibitors (NIs) (costing approximately £18 per course) could affect marked savings in this group and consequently NIs will now be used therapeutically in the UK for the 'at risk' community. However, a wider use in the hitherto unprotected 'worried well' group may also be a sensible public health approach but is currently not common practice. Such a wider use of NIs would undoubtedly encourage the development of further drugs in this series. For example, peramivir was shown to be as or even more potent in vitro compared with zanamivir and oseltamivir (Boivin & Goyette, 2002; Gubareva et al., 2001) and Phase II trials were promising. Phase III clinical trials were, however, less successful and BioCryst in USA has for the moment ended a collaboration with Johnson & Johnson and halted further development. This halt may also reflect company perceptions that the potential market for NIs is still small, at least at present. The fact that peramivir was such a strong inhibitor in the laboratory compared with the other two drugs on the market would indicate that there is room for improvement in the design of effective NIs. Similarly, Abbott Laboratories had invested in a novel pyrrolidine-based inhibitor (structure not shown) called A-315675 or ABT-675. This drug dissociated more slowly from influenza A and B neuraminidase than oseltamivir and was also a potent inhibitor, particularly against influenza B strains . There was also minimal cross-resistance between A-315675/ABT-675-and oseltamivir-selected variants . Abbott too has temporarily halted development of this anti-NA drug, most likely because of financial reasons. On the contrary, Biota (Australia), is investigating a new NI called FLUNET (structure not shown). This molecule is a dimerised zanamivir. Initial data indicates that it is 100-times more potent than zanamivir in vitro, it is retained longer in animal lungs compared with zanamivir, that one dose protects animals for at least 1 week and that one dose is also more effective than two doses of zanamivir for therapy of influenza infections (from www.biota.com).
Pharmacokinetics and clinical safety of NIs
Of course a drug that is to be useful against clinical influenza, which even in the 'at risk' group is more frequently nonlethal than lethal, must have a very high safety profile. To date, both zanamivir and oseltamivir have proven to be safe drugs and have been administered around the world in hundreds of thousands of doses. At present, less is known about peramivir. However, no drug is completely free of problems. A concern about zanamivir has been exacerbation of reactive airways disease. Bronchospasm has been described in a few patients with pre-existing respiratory disorders, such as asthma or chronic obstructive airways disease, using the inhaler (Cheer & Wagstaff, 2002) . No convincing evidence, however, exists of development of bronchospasm in otherwise healthy individuals following drug administration. Compliance with the inhaler has been excellent although it is recognised that young children and the very frail elderly may have problems with the breathactivated device. Oseltamivir causes some upper gastrointestinal effects such as nausea and these effects are noted after the first dose and usually resolve after 24-48 h. Problems can be avoided by eating a biscuit at the time of oral dosing. Both zanamivir and oseltamivir deliver high levels of the active inhibitor in the respiratory tree of humans. More than 1000 ng/ml of zanamivir is detected in the sputum and is detectable for 24 h. Low plasma levels are detectable (Cass et al., 1999) . Oseltamivir is an ethyl ester prodrug that is well absorbed and rapidly metabolised by liver esterases, giving around 80% bioavailability. The drug peaks 3-4 h post-dosing with levels of 350 ng/ml in adults after a typical dose of 75 mg. The plasma half-life approximates to 6-10 h (He et al., 1999) .
Clinical management of influenza
The original investigations with the first anti-influenza drug amantadine and rimantadine (the M2 blockers) showed clearly that antivirals could be used to prevent infection in the work place or family (Galbraith et al., 1969) , or to treat already established infection. The idea that a drug could abrogate the symptoms of influenza was strongly contested at the time but it became quite clear that intervention with amantadine 24-48 h after the onset of symptoms could reduce time in bed, cough and viral titre. Less controversial at the time were studies showing that judicious use in the family after identification of a member with influenza (index case) could reduce the spread by 80% or more (Galbraith et al., 1969) . This sensible intervention is now called post-infection prophylaxis (Welliver et al., 2001) because it is recognised that most family members would have already been infected by the index case before drug intervention. Table 3 summarizes five placebo-controlled prophylactic studies of zanamivir and oseltamivir carried out mainly in the USA and Europe. Overall, the protective effect of both drugs varies between 60 and 90%, suggesting very clearly that these drugs can be used effectively in the community. There is less evidence of use in vulnerable settings such as homes for the elderly but there is no clear reason why the new inhibitors should not be very effective.
Some typical data from clinical trials of the use of the new drugs in chemotherapy are shown in Tables 4, 5 and 6. Clinical studies in the community showed that administration of inhaled drugs within 48 h of natural influenza A or B infection significantly reduced the duration of symptomatic illness by 1 day (4 versus 5 days) compared with placebo. Importantly, data also indicated that zanamivir treatment reduced the impact of influenza virus infection on a patients' productivity and health status and the number of contacts made with healthcare professionals (Elliott, 2001; Hayden et al., 1997; Makela et al., 2000; MIST Study Group, 1998; Monto et al., 1999a) . To study the therapeutic effect of zanamivir Monto et al. (1999b) analysed the overall intent-to-treat (ITT) population and showed that the drug reduced the median number of days to alleviation of clinically significant symptoms by 1 day compared with placebo (6 versus 7 days; Table 4 ). For patients who began treatment >30 h after onset of symptoms, the difference between zanamivir and placebo groups, although still present, was reduced to 0.5-1 day; this difference was not statistically significant. Zanamivir reduced the time to symptom alleviation in both febrile and non-febrile patients but had a greater effect on febrile patients. Zanamivir given twice daily reduced the median time for alleviation of symptoms by 0.75 day in the nonfebrile group (P=0.049) and by 1.5 day in the febrile group (P=0.049). Similar differences were seen for zanamivir 4times daily, compared with placebo. Similar benefits regarding symptom alleviation were seen in the corresponding analyses for the influenza-positive population. A reduction of 1.5 day in the time to symptom alleviation was seen in both zanamivir groups for the total influenza-positive population, although the differences were not statistically significant.
In comparable studies of oseltamivir in the community (Treanor et al., 2000) a total of 629 healthy, unimmunized adults aged 18-65 year presenting within 36 h of onset and with a temperature of 38°C or more plus at least one respiratory symptom and one constitutional symptom were enrolled (Table 5 ). Individuals were randomized to one of three treatment groups: oseltamivir 75 mg twice daily, oseltamivir 150 mg twice daily for 5 day or placebo. A total of 374 participants were confirmed to have influenza (60%). Duration of illness from the initiation of therapy was reduced by approximately 30% in the oseltamivir groups. In the 75 mg twice daily group, the median duration of illness was reduced to 3 day compared with 4.3 day in the placebo group (P=0.001) and in 150 mg twice daily group the duration was reduced to 2.9 day (P=0.001). There was also a significant decrease in the symptom score AUC as a measure of the severity of illness. Volunteers treated with oseltamivir reported more rapid return to normal health and usual activities. Additionally, the incidence of secondary complications, predefined as pneumonia, bronchitis, sinusitis and otitis media, in subjects with influenza was reduced from 15% in placebo recipients to 5-9% in the two oseltamivirtreated groups. Antibiotic prescriptions for these complications were reduced (Table 6 ).
Role of the NIs against pandemic influenza
Consciously, or unconsciously underlying much of the scientific endeavour with influenza A are the bewildering and frightening consequences of the Great Spanish Influenza Pandemic of 1918. In fact, our own studies have shown that this virus did not originate in Spain in 1918 but rather in Northern France in 1916/1917 (Oxford, 2000; but its notoriety as the Spanish Lady is unlikely to be changed. For a virus to suddenly direct its pathogenicity and virulence to a particular age group and then, just as suddenly to revert to the norm of epidemic influenza is unique. Of course the world of 1918 was very particular with millions of young men returning home in overcrowded trains and troopships (Crosby, 1999) . There probably had never been so many people travelling by sea and there will never be again in the future. On arrival their parents in South Africa, Australia and New Zealand often gave celebratory parties and again the virus had a unique chance to spread, even into otherwise quite isolated rural homesteads ( Johnson, 2001) . In the Black October outbreak in South Africa where the virus spread along the railways, 250000 people died in 4 weeks (Phillips & Killingray, 2002) . In total at least 50 million citizens died in every country of the world. We have argued that the cir-cumstances of the Great War itself allowed and even encouraged the emergence of this Great Pandemic virus . The wounded survivors of the gascontaminated battlefields of the Somme, German and English alike, gathered together in 24 hospitals of the Great City British Army Camp of Etaples in Northern France, in close proximity to each other, to transport horses, to the live duck, geese and poultry markets of the area and to the new pig farms installed in the army camp itself. This convergence could have created the special circumstances for genetic mixing, re-assortment and cross-species transfer of a new influenza A virus. For example, the same social and virological circumstances were present in Hong Kong in 1997 when an avian influenza A virus crossed the species barrier and killed six humans (Yuen et al., 1998) . Molecular analysis of mutation rates of HA, NA and NP genes from studies from 1918 samples also imply that the virus emerged sometime after 1915 and before 1918 (Reid et al., 1999) . Perhaps the most important observations come from the pathologists and bacteriologists in the Royal Army Military Corps who observed the early epidemics as waves in Etaples (Hammond et al., 1917) and Aldershot (Abrahams et al., 1917) barracks and then experienced the great wave of 1918 and finally concluded that they were exactly the same disease (Abrahams et al., 1919) . This scientific interest in the 1918 virus, which has led to nucleotide analysis of four genes would be of only historic and geographic interest were if not for the fact that WHO has requested each nation to plan now for the next influenza A virus pandemic. Advance notice of an outbreak would allow rapid synthesis of large quantities of antivirals and also production of some vaccine and therefore the question of surveillance becomes of critical importance. Where will the next pandemic influenza A virus arise? Only 15 nations are known to have a plan but the UK has thought carefully and has two published plans (PHLS, 1993 ; and www.phls.co.uk/publications/pdf/pandemicplan.pdf ).
There has been a very simplistic viewpoint that because the 1957 and the 1968 pandemics appeared to originate in Asia that the next virus would also emerge there. This reasoning has been taken further to speculate that the 1918 virus also originated in China perhaps even travelling to Europe including Etaples with the Chinese labourers who built the camp there in 1916. This is potentially an important criticism and demands a response. In fact, Chinese labourers were at the Etaples and other camps to build them in 1916 and to demolish them in 1918. However the most recent analysis uncovers no evidence of widespread influenza on China up to 1918 (Phillips & Killingray, 2002 and concludes that the virus spread eastwards from Europe to China. Both the time of evolution of pandemics and the geographical origin of the epicentre are vital factors in relation to decisions on the relative use of vaccines and antivirals.
The NIs inhibit viruses of all 15 subtypes of influenza A and also influenza B. Therefore, one can conclude that the NIs could be used in future pandemics. Should a future pandemic virus emerge from an avian reservoir we have to consider that such a virus could have a degree of pantropism and could infect other organs in addition to the respiratory tract. In this case the oral NIs, which distribute more widely in the body, may have a therapeutic advantage compared with zanamivir, which is mainly deposited in the respiratory tract. There was some anecdotal information that the 1918 virus was pantropic but careful examination of post mortem samples from victims does not support this assertion with the single possible example of the brain (Winternitz et al., 1920) .
Genetic analysis of the NA of 1918 influenza has established that, remarkably, the NIs would have inhibited the virus because the enzyme active site is conserved in this virus and is similar to other influenza A viruses (Reid et al., 2000) . Initial genetic analysis of HA, NA, M and NS1 genes of the 1918 pandemic virus has failed to detect any definitive virulence motif or characteristic. The virulence could yet reside in the polymerase genes PA, PB1 or PB2, or be a result of interaction of several genes, each with relatively minor changes in nucleotide sequence. Biological studies with the NS1 gene have also failed to attribute the excessive virulence of the 1918 virus to this particular gene (Basler et al., 2001; Geiss et al., 2002) . The authors hypothesised that should the 1918 NS1 gene have had a mutation to enhance its normal effect, namely to block type I IFN, then this should explain the rapid clinical course of the disease at that time. However, when recombinant influenza A viruses were tested for virulence in a mouse model in a high security laboratory no enhancement of virulence was detected when the 1918 NS1 gene was substituted for WSN/33 NS1 gene. Interestingly, pigs infected with H1N1 recombinant influenza viruses carrying the 1997 H5N1 NS1 gene, showed evident signs of viral infection compared with control infected pigs (Seo et al., 2002) .
Uses of NIs in inter-pandemic years
Simple arithmetic will indicate that influenza deaths and hospitalisation in the years between pandemics far exceed those of the pandemic wave itself. This was certainly the case in the UK between 1918 and 1957 where there were 250000 deaths in the three great pandemic waves of 1918-1919 but in excess of 400000 deaths over the next 38 years from the drifted, now epidemic, influenza A (H1N1) virus and, intermittently, influenza B viruses. It has also became quite apparent that only if influenza is managed correctly in the inter-pandemic years will it be possible to have successful chemo-and immuno-prophylaxis and chemotherapy against a new pandemic virus. To give an indication, the current use of influenza vaccine in the UK is 15 million doses of trivalent vaccine. Four years ago only half this quantity of vaccine was produced. Thus, the UK has the production capacity now, for the first time, to produce enough of the monovalent pandemic influenza A virus to protect 45 million citizens and probably with a judicious dilution and use of whole virus vaccine, the whole population. The situation with the NIs and M2 blockers is more parlous with oseltamivir only recently licensed in the EU and the NICE committee in the UK (www.nice.org.uk) disencouraging the use of the NI drugs in the wider community in the yearly epidemics. It would not be a sensible decision only to stockpile drugs for pandemics and not gain clinical and scientific experience during the intervening inter-pandemic period.
Drug resistance and the NIs
It has been presumed, given the quasi-species nature of influenza, that virus resistant to the NIs existed even before the drugs were discovered. However to date no such viruses have been uncovered. Rather, quite extensive laboratory passage of influenza A and B virus in cell culture is required to select an NI-resistant mutant. Some mutants have also been recovered from patients but only infrequently and only after stringent efforts were made to isolate them. Most significant, however, is the observation that the drug-resistant mutants are somewhat compromised in virulence. Animal model experiments in mice and ferrets have shown the drug-resistant mutants to be less virulent or pathogenic Ives et al., 2002) and also less transmissible. Table 7 summarizes the most frequent mutations to date on the NA, which are at amino acid positions 119, 152, 274 and 292. These are all highly conserved amino acids at/or near the NA enzyme active site. The HA and NA are fascinatingly interdependent molecules. The HA depends on binding to sialic acid at the critical stage of virus adsorption to a cell and yet NA cleaves off this receptor and so allows the virus to be released at budding. Not surprisingly, the two molecules can compensate for each other. Thus, given a blockage of NA by a drug only virus with HA that binds weakly will be released from a cell. To some extent this virus can exist without a fully functional NA molecule and so the virus can escape the effects of NIs. In the presence of NI pressure mutations in the HA close to the receptor binding site reduce binding efficacy to cell receptors.
The most common mutation in the NA gene selected by exposure to NA inhibitors in vitro is an amino acid substitution of a lysine (K) instead of a conserved arginine (R) at position 292, in influenza N2 NA. The R292K mutation has been selected by oseltamivir carboxylate, zanamivir and peramivir. An H274Y mutation in H1 has also been selected in vitro by oseltamivir carboxylate and in vivo in an H1N1 influenza virus challenge study with oseltamivir phosphate in healthy volunteers. The most common N2 mutation, which arises in vitro under selective pressure of zanamivir, has been that of the conserved Glu119 residue Gubareva et al., 2002. in the NA active site, causing a 100-fold reduction in the sensitivity of the enzyme to zanamivir. Importantly, virus carrying the zanamivir-selected mutation is attenuated in infectivity in mice and in pathogenicity in ferrets. There are no mutations selected by oseltamivir carboxylate at position 119 in vitro, but E119V has arisen clinically during oseltamivir phosphate treatment in just two patients infected with influenza A virus of the H3N2 subtype. No NA mutations giving rise to resistance have yet been generated by oseltamivir in influenza B NA in vitro, although there is some evidence that zanamivir in vivo has induced development of a resistant mutation in influenza B NA in an immunocompromised child (Gubareva et al., 1998a) . The incidence of resistant virus has been shown to be low and resistant virus where it does occur is detected only transiently, arising late in infection and being cleared normally.
In one clinical study in which 385 patients were treated for naturally acquired infection (Treanor et al., 2000) only one patient was found to shed virus, which carried NA with reduced sensitivity to oseltamivir. This patient received 75 mg twice daily oseltamivir phosphate. The virus isolated from a post-treatment nasal swab carried NA with the R292K mutation. The overall fitness (infectivity, replicative ability, pathogenicity and transmission) of the virus carrying the R292K mutation in the neuraminidase gene was reduced in both mouse and ferret models of influenza (Herlocher et al., 2002) . The other NA mutations that have arisen with oseltamivir treatment of naturally acquired influenza infection, again with low frequency, are H274Y (one patient) and E119V (two patients). As for patients carrying R292K virus, there was no change in symptom score and recovery for the patients with H274Y and E119V in the neuraminidase.
Events in the USA in September-November 2001 indicate how modern societies react to unexpected outbreaks of potentially lethal disease
A presumed scientist with access to deliberately processed anthrax spores has exposed cruelly how an entire society in the new century reacts to potentially hazardous microbes. The recent edge of panic reaction was very different from the events of 1918 where 500000 persons died in the USA. We can see that demand for antivirals to use in prevention during an influenza pandemic in the 21st century would be very considerable. Therefore, we conclude that a minimal investment in pandemic planning would be a stockpile, in the UK for example of 20 million courses of antivirals perhaps a 3:1 proportion of NIs and M2 blockers. The total cost would approximate to £200 million, which is a rather small financial investment, to avert chaos, hospitalisation and death. Of course, such a strategic pandemic investment plan would include preparations for vaccine manufacture including at the very least, re-assortant strains for the 15 known influenza HAs, with high growth capacity in eggs and also some forward investment in a mammalian cell culture facility to produce MDCK or Vero cell influenza vaccine on a large scale. Certainly the UK could within 1 year produce enough influenza vaccine for every citizen. In this scenario the anti-influenza drugs would be used initially to combat the first wave of the outbreak and, in later waves as an adjunct to vaccine to counteract breakthrough viruses ( Table 8 ).
The future
A long-term investment in pure research by the Australian government in particular led through a series of purely academic discoveries of the nature and atomic structure of the influenza NA molecule to a new series of influenza inhibitors. The small Australian biotech company, Biota, was able to exploit the discovery of zanamivir and, jointly with GlaxoSmithKline, to invest £300 million to perform safety testing and controlled clinical trials. A similar collaboration was established between Gilead Sciences and Roche to develop oseltamivir. This series of NIs are also the first antiviral compounds to be designed with the aid of computers. This is a group of powerful drugs exerting antiviral effects before cell entry and at virus release. These antiviral effects translate into economic benefit in preventing disease or shortening the duration of the clinical signs of influenza in the 'at risk' groups and working community. Importantly, the latter huge sector, which at present has not been able to receive influenza vaccine, now has the opportunity to look after their own health and that of their family. It is a comforting thought that when the next Great Pandemic emerges at least some nations of the world will have protection for their citizens because they have placed sensible resources into pandemic planning and stockpiled virus strains for vaccines and antiviral drugs for immediate use in the first great lethal waves. Table 8 . Minimal preparation for a pandemic: antiviral drugs An active national plan reviewed and updated yearly. A thoughtful and coherent priority listing of recipients of vaccine and antiviral prophylaxis if these are in short supply. A circulating stockpile of NIs and M2 blockers equivalent to a third of the national population (priority use). A contingency plan for rapid synthesis of NIs and M2 blockers for the remaining two thirds of the national population. Increased use of NIs and M2 blockers in the inter-pandemic years to gain clinical experience with the drugs.
